Table 14Efficacy outcomes of sitagliptin monotherapy compared with placebo

Author, yearChange in HbA1c from baseline at (%)Change in weight from baseline (kg)
Hanefeld, 20074612 weeks12 weeks
−0.28−0.44−0.44−0.430.12−0.5 to −0.8−0.5
12 weeks12 weeks
Chan, 200837−0.6−0.10−0.6
12 weeks12 weeks
Nonaka, 200844−0.65+0.41−0.1−0.7a
Scott, 200730−0.54+0.23NRNR
18 weeks18 weeks
Raz, 200643−0.48+0.12−0.6−0.7
Mohan, 200945−0.7+0.3+0.60
24 weeks24 weeks
Aschner, 200642−0.61a+0.18−0.2−1.1a
Goldstein, 200731−0.66a+0.170.0−0.9a

Abbreviation: NR, not reported; PBO, placebo; S25, sitagliptin 25mg daily; S50, sitagliptin 50mg daily, S100, sitagliptin 100 mg daily; S50BID, sitagliptin 50 mg twice daily; S25/50, sitagliptin 25 or 50 mg daily.


P<0.001 for sitagliptin compared with placebo.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.